EVMN
Evommune, Inc.Company with tickers: EVMN
CIK
2044725
CUSIP
30054Y107
Shares Outstanding
36,018,372
13F Activity (30d)
62 filings
62 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $23,954,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $17,319,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-23,954,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-21,674,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.64 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.64 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |